IMR Press / EJGO / Volume 42 / Issue 5 / DOI: 10.31083/j.ejgo4205129
Open Access Original Research
Effectiveness of human epididymis protein 4 (HE4) as predictor of response to first line platinum based chemotherapy
Show Less
1 Department of Obstetrics and Gynecology, University of Rome “Campus Bio-Medico”, Via Alvaro del Portillo, 200-00128 Rome, Italy
2 Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, “Sapienza” University of Rome, 00186 Rome, Italy
3 Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Lazio, Italy
Eur. J. Gynaecol. Oncol. 2021, 42(5), 844–849;
Submitted: 29 January 2021 | Revised: 19 May 2021 | Accepted: 20 May 2021 | Published: 15 October 2021
(This article belongs to the Special Issue The Role of Biomarker in Gynecological Oncology)

Objective: To assess the role of HE4 (Human epidydimal protein 4) marker as predictor of response to platinum based chemotherapy. Methods: In the current observational prospective study, 35 patients affected by High Grade Serous Ovarian Cancer (HGSOC) were enrolled; among these, 17 patients were platinum sensitive, while 18 were platinum resistant. HE4 levels were measured before surgery, at the III and at the VI cycle of chemotherapy. Results: The reduction of 50% or more of HE4 levels at the III cycle of chemotherapy showed a specificity of 100% and a sensitivity of 27%. The negativization (<70 pmol/L) of HE4 at the III cycle of chemotherapy showed a specificity of 100%, with a sensitivity of 39%, in predicting chemotherapy response, while the same parameter at the VI cycle showed a specificity of 82% and a sensitivity of 67%. Moreover the ROC analysis identified the HE4 cut-off value of 62.79 pmol/L as the best cut-off in predicting chemotherapy response, with a sensitivity of 72% and a specificity of 88% at the III cycle. Discussion: Our results suggest that HE4 levels during first-line chemotherapy, in particular at the III cycle, could predict chemotherapy response in HGSOC patients.

Ovarian cancer
Fig. 1.
Back to top